Phio Pharmaceuticals, Inc. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on advancing a new class of gene modulation therapies and immuno-oncology agents. Built upon proprietary deoxyribonucleic acid directed RNA interference (ddRNAi) technology, Phio is developing a pipeline of bifunctional oligonucleotides designed to both silence disease-related genes and simultaneously engage the patient’s immune system. This innovative dual mechanism aims to improve the safety, specificity and durability of treatments especially in oncology settings.
Headquartered in Malvern, Pennsylvania, Phio leverages strategic partnerships and in-house expertise to advance its core programs. The company’s lead candidates include PH-762, a cancer vaccine that harnesses ddRNAi for targeted immune priming, and various next-generation oligonucleotides addressing solid tumors and hematologic malignancies. Preclinical and early clinical data support the potential for combination regimens alongside established checkpoint inhibitors.
Founded in 2015 as a spin-out from leading academic institutions, Phio has built a management team with deep experience in drug development, regulatory strategy and commercial planning. Under the leadership of President and CEO Len G. Hickey, the organization continues to expand its research capabilities, engage with external collaborators and explore novel applications of RNAi technology across multiple therapeutic areas.
Phio Pharmaceuticals maintains a focus on advancing its assets through rigorous clinical studies while exploring strategic collaborations to maximize the impact of its ddRNAi platform. As the company progresses through key clinical milestones, it aims to offer differentiated treatment options for patients with high unmet medical needs in the oncology landscape.
AI Generated. May Contain Errors.
Free PHIO Stock Alerts